Fenbendazole for humans has been gaining popularity after it was used by a cancer patient to cure his disease. This “worm-eating” medication belongs to the benzimidazole class of drugs and was initially developed to treat parasites in animals. An increasing number of research and published studies have revealed that this drug also has cancer-fighting properties in humans.
In particular, fenbendazole is effective against a variety of cancer cells, including prostate, colorectal, and pancreatic cancers. A slew of new publications and studies have emerged, revealing that the anthelmintic medication can essentially starve cancerous cells by interrupting their access to glucose. This results in the cell’s death or apoptosis, as the body naturally eliminates these abnormal cells.
Furthermore, the anthelmintic drug has been shown to promote regression in human cancer patients who have large B-cell lymphoma that has metastasized, as well as bladder and renal cell carcinoma. These findings are encouraging, and researchers are continuing to search for additional ways to use fenbendazole to fight cancer.
Interestingly, fenbendazole has been found to induce autophagy in colorectal cancer cells. The anthelmintic drug stimulates Beclin-1 expression in the cells, which leads to LC3-I and Atg7 upregulation. Moreover, it also prevents apoptosis.
It is important to note that this research is only preliminary and that no fenbendazole for cancer treatment has been approved by the FDA. However, many doctors have begun to utilize fenbendazole for their cancer patients, as it appears to offer promising results with little toxicity. Developing new cancer medications is an incredibly lengthy process and can take years to be brought to market. This is why it’s encouraging to see a treatment that offers promising results at such a low price point. fenbendazole for humans